Kura Oncology (NASDAQ:KURA) Shares Gap Up - Should You Buy?

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $5.69, but opened at $5.95. Kura Oncology shares last traded at $5.81, with a volume of 285,233 shares changing hands.

Analyst Ratings Changes

KURA has been the subject of a number of analyst reports. Barclays cut their target price on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Monday, April 28th. Wall Street Zen lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. UBS Group cut their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Finally, Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Kura Oncology has an average rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Stock Performance

The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average price of $6.06 and a two-hundred day moving average price of $7.75. The company has a market capitalization of $582.65 million, a price-to-earnings ratio of -2.85 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. As a group, analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. BVF Inc. IL grew its stake in shares of Kura Oncology by 202.0% during the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock valued at $51,177,000 after buying an additional 5,186,660 shares during the period. RA Capital Management L.P. purchased a new stake in Kura Oncology during the fourth quarter valued at about $38,769,000. Millennium Management LLC increased its stake in Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after acquiring an additional 1,521,954 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Kura Oncology in the 4th quarter worth about $8,518,000. Finally, Marshall Wace LLP acquired a new position in shares of Kura Oncology in the 4th quarter valued at about $8,265,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.